• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A case with systemic juvenile idiopathic arthritis treated with tofacitinib and rapamycin.

作者信息

Cam Veysel, Sag Erdal, Bilginer Yelda, Ozen Seza

机构信息

Division of Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey.

出版信息

Rheumatology (Oxford). 2025 Apr 1;64(4):2315-2316. doi: 10.1093/rheumatology/keae637.

DOI:10.1093/rheumatology/keae637
PMID:39579141
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11962887/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec3/11962887/587bffd2ea5c/keae637f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec3/11962887/587bffd2ea5c/keae637f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec3/11962887/587bffd2ea5c/keae637f1.jpg

相似文献

1
A case with systemic juvenile idiopathic arthritis treated with tofacitinib and rapamycin.一例使用托法替布和雷帕霉素治疗的全身型幼年特发性关节炎病例。
Rheumatology (Oxford). 2025 Apr 1;64(4):2315-2316. doi: 10.1093/rheumatology/keae637.
2
Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report.托珠单抗和托法替布序贯治疗全身型幼年特发性关节炎：一例报告
Rheumatol Ther. 2023 Feb;10(1):293-300. doi: 10.1007/s40744-022-00496-z. Epub 2022 Nov 29.
3
Tofacitinib treatment of systemic juvenile idiopathic arthritis: a case report and literature review.托法替布治疗全身型幼年特发性关节炎：一例报告及文献综述
Front Pediatr. 2025 Feb 13;13:1482762. doi: 10.3389/fped.2025.1482762. eCollection 2025.
4
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.托法替尼治疗幼年特发性关节炎：一项双盲、安慰剂对照、撤药阶段 3 随机试验。
Lancet. 2021 Nov 27;398(10315):1984-1996. doi: 10.1016/S0140-6736(21)01255-1. Epub 2021 Nov 9.
5
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.托法替布在多关节型幼年特发性关节炎儿童中的药代动力学和安全性：一项1期开放标签多中心研究的结果
Pediatr Rheumatol Online J. 2017 Dec 28;15(1):86. doi: 10.1186/s12969-017-0212-y.
6
Safety and Effectiveness of Tofacitinib in Treating Polyarticular Course Juvenile Idiopathic Arthritis.托法替布治疗多关节型幼年特发性关节炎的安全性和有效性
Cureus. 2023 Nov 4;15(11):e48258. doi: 10.7759/cureus.48258. eCollection 2023 Nov.
7
Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: Extended experience from Bangladesh.托法替布治疗难治性多关节型幼年特发性关节炎：来自孟加拉国的扩展经验。
PLoS One. 2025 Jan 24;20(1):e0312174. doi: 10.1371/journal.pone.0312174. eCollection 2025.
8
Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: A study from Bangladesh.托法替尼治疗多发性关节病程幼年特发性关节炎难治病例的疗效和安全性：来自孟加拉国的一项研究。
Int J Rheum Dis. 2022 Jun;25(6):678-684. doi: 10.1111/1756-185X.14324. Epub 2022 Apr 18.
9
Juvenile Idiopathic Arthritis Treatment Updates.青少年特发性关节炎治疗进展
Rheum Dis Clin North Am. 2021 Nov;47(4):545-563. doi: 10.1016/j.rdc.2021.07.009. Epub 2021 Sep 2.
10
Beneficial Effect of Upadacitinib in an Adult Patient with Juvenile Idiopathic Arthritis-associated Uveitis after Unsatisfactory Response to Tofacitinib: A Case Report.托法替尼治疗反应不佳的幼年特发性关节炎相关葡萄膜炎成人患者应用乌帕替尼的疗效：病例报告。
Ocul Immunol Inflamm. 2023 Jul;31(5):1079-1080. doi: 10.1080/09273948.2022.2069128. Epub 2022 May 19.

引用本文的文献

1
T-ing up the storm: pathogenic cycling lymphocytes in the biology of macrophage activation syndrome.引发风暴：巨噬细胞活化综合征生物学中的致病性循环淋巴细胞
Pediatr Rheumatol Online J. 2025 Mar 17;23(1):29. doi: 10.1186/s12969-025-01081-8.

本文引用的文献

1
Recent advances and evolving concepts in Still's disease.斯蒂尔病的最新进展和不断发展的概念。
Nat Rev Rheumatol. 2024 Feb;20(2):116-132. doi: 10.1038/s41584-023-01065-6. Epub 2024 Jan 11.
2
Efficacy and safety of emapalumab in macrophage activation syndrome.埃马鲁单抗治疗巨噬细胞活化综合征的疗效和安全性。
Ann Rheum Dis. 2023 Jun;82(6):857-865. doi: 10.1136/ard-2022-223739. Epub 2023 Mar 31.
3
mTORC1 links pathology in experimental models of Still's disease and macrophage activation syndrome.mTORC1 将斯蒂尔病和巨噬细胞活化综合征的实验模型中的病理学联系起来。
Nat Commun. 2022 Nov 28;13(1):6915. doi: 10.1038/s41467-022-34480-6.
4
Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease.全身性幼年特发性关节炎难治性病程的发病机制和治疗：难治性关节炎、复发性巨噬细胞活化综合征和慢性肺病。
Rheum Dis Clin North Am. 2021 Nov;47(4):585-606. doi: 10.1016/j.rdc.2021.06.003. Epub 2021 Aug 21.
5
Refractory systemic juvenile idiopathic arthritis successfully treated with rapamycin.雷帕霉素成功治疗难治性系统性幼年特发性关节炎。
Rheumatology (Oxford). 2021 Jul 1;60(7):e250-e251. doi: 10.1093/rheumatology/keab114.
6
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.开放性、多中心、剂量递增的Ⅱ期临床试验，评估替德西利单抗（IL-18BP）治疗成人斯蒂尔病的安全性和疗效。
Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22.